BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25800731)

  • 1. Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment.
    Basile U; Gragnani L; Piluso A; Gulli F; Urraro T; Dell'Abate MT; Torti E; Stasi C; Monti M; Rapaccini GL; Zignego AL
    Liver Int; 2015 Sep; 35(9):2100-7. PubMed ID: 25800731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders.
    Terrier B; Sène D; Saadoun D; Ghillani-Dalbin P; Thibault V; Delluc A; Piette JC; Cacoub P
    Ann Rheum Dis; 2009 Jan; 68(1):89-93. PubMed ID: 18375535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia.
    Oliveira IS; Cabral MS; Jesus LS; Paraná R; Atta AM; Sousa Atta ML
    Braz J Infect Dis; 2014; 18(6):638-42. PubMed ID: 25193081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders.
    Gulli F; Basile U; Gragnani L; Fognani E; Napodano C; Colacicco L; Miele L; De Matthaeis N; Cattani P; Zignego AL; Rapaccini GL
    Dig Liver Dis; 2016 Aug; 48(8):927-33. PubMed ID: 27289333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
    Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
    Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.
    Saadoun D; Aaron L; Resche-Rigon M; Pialoux G; Piette JC; Cacoub P;
    AIDS; 2006 Apr; 20(6):871-7. PubMed ID: 16549971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia.
    Basile U; Gulli F; Napodano C; Pocino K; Basile V; Marrapodi R; Colantuono S; Todi L; Marino M; Rapaccini GL; Visentini M
    Biotechnol Appl Biochem; 2021 Apr; 68(2):319-329. PubMed ID: 32333692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.
    Gragnani L; Cerretelli G; Lorini S; Steidl C; Giovannelli A; Monti M; Petraccia L; Sadalla S; Urraro T; Caini P; Xheka A; Simone A; Arena U; Matucci-Cerinic M; Vergani D; Laffi G; Zignego AL
    Aliment Pharmacol Ther; 2018 Aug; 48(4):440-450. PubMed ID: 29952013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
    Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
    Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation.
    Saadoun D; Landau DA; Calabrese LH; Cacoub PP
    Rheumatology (Oxford); 2007 Aug; 46(8):1234-42. PubMed ID: 17566058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.
    Gragnani L; Piluso A; Urraro T; Fabbrizzi A; Fognani E; Petraccia L; Genovesi A; Giubilei L; Ranieri J; Stasi C; Monti M; Zignego AL
    Curr Drug Targets; 2017; 18(7):772-785. PubMed ID: 26853322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
    Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
    Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
    Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
    Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between Vitamin D status and free light chains profile with different chronic HCV-related liver and extrahepatic disorders.
    Basile U; Napodano C; Pocino K; Barini A; Marino M; Santini SA; Barini A; Stefanile A; Basile V; Callà CA; Cattani P; Gasbarrini A; Rapaccini GL; Gulli F
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8506-8514. PubMed ID: 31646582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.
    Stasi C; Triboli E; Arena U; Urraro T; Petrarca A; Gragnani L; Laffi G; Zignego AL
    J Transl Med; 2014 Jan; 12():21. PubMed ID: 24456582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)].
    Ghinoi A; Mascia MT; Puccini R; Ferri C
    G Ital Nefrol; 2004; 21(3):225-37. PubMed ID: 15285001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.